Fase II trial with gemcitabine and oxaliplatin in patients with unknown primary tumours - UPT - unfit
Phase 1
- Conditions
- To test the effect of Gemcitabine and axaliplatin in patients with unknown primary tumours and performance 2 or age 66 to 75
- Registration Number
- EUCTR2005-001959-38-DK
- Lead Sponsor
- Gedske Daugaard
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
Unknown primary tumour
Performance 2 or age 66 to 75
Measurable lesion by RECIST
Expected life time more than 12 weeks
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Performance 0 or 1 and age below 66
neuropathy
another known cancer disease
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: response rate<br>;Secondary Objective: side effects<br>time to progression;Primary end point(s): response rate
- Secondary Outcome Measures
Name Time Method